Navamedic ASA

NAVA

NO0010205966

Pharmaceuticals

Market Closed - Oslo Bors Other stock markets 08:15:00 27/05/2024 pm IST			5-day change	1st Jan Change
34.5 ^NOK	0.00%		+1.47%	-5.99%

06/05	Navamedic Rolls Out Erectile Dysfunction Drug in Sweden	MT
30/04	Navamedic ASA Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Navamedic ASA Appoints Tom Rönnlund as New Ceo, Effective May 18, 2015

April 23, 2015 at 07:35 pm IST

Tom Rönnlund has been appointed new CEO of Navamedic ASA. Tom Rönnlund joins the company from IMS Health Inc., where he held the position of General Manager for the Nordic & Baltic Region. Tom Rönnlund assumes his new responsibilities at the company on 18 May 2015.

Latest news about Navamedic ASA

Navamedic Rolls Out Erectile Dysfunction Drug in Sweden	06/05	MT
Navamedic ASA Reports Earnings Results for the First Quarter Ended March 31, 2024	30/04	CI
Ingerø Reiten Investment Divests Navamedic Stake in NOK95 Million Deal	13/03	MT
An unknown buyer acquired unknown minority stake in Navamedic ASA (OB:NAVA) from Ingerø Reiten Investment Company As for NOK 95 million.	12/03	CI
Navamedic ASA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	15/02	CI
Navamedic Acquires Rights to Distribute Erectile Dysfunction Treatment in Nordic Countries	12/02	MT
Navamedic ASA Acquires Rights to Market and Distribute Eroxon in the Nordic Countries	12/02	CI
Navamedic ASA Renews Contract Signed with Vitaflo International Limited	21/12	CI
Navamedic Enters Agreement with Orion for Distribution of Parkinson's Drug Across Europe	14/12	MT
Navamedic ASA and Orion Corporation Sign Non-Binding Term Sheet for Flexilev® in Europe	13/12	CI
Navamedic ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	01/11	CI
Navamedic ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Navamedic ASA Elects Åsa Kornfeld as Members of its Board of Directors	01/23/01	CI
Navamedic Secures Ownership of Sweden’s Sensidose	26/23/26	MT
Navamedic ASA (OB:NAVA) completed the acquisition of Sensidose AB.	25/23/25	CI
EQL Pharma Closes Sensidose Bid, to Accept Navamedic Offer	17/23/17	MT
Navamedic ASA Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11	CI
Norway's Navamedic Lifts Offer for Remaining Sensidose Shares	10/23/10	MT
Sweden’s EQL Pharma Increases Bid for Sensidose	24/23/24	MT
Navamedic Raises Takeover Offer for Sensidose, Agrees to Buy 57% Stake	24/23/24	MT
Navamedic Offers to Buy Sensidose for SEK75 Million	29/23/29	MT
Navamedic ASA (OB:NAVA) made an offer to acquire Sensidose AB for SEK 96 million.	29/23/29	CI
Navamedic ASA Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	16/23/16	CI
Navamedic ASA Reports Earnings Results for the Full Year Ended December 31, 2022	16/23/16	CI
Navamedic ASA Launches Modifast in Norway	30/23/30	CI

Chart Navamedic ASA

Duration

Period

More charts

Company Profile

Navamedic ASA is a Norway-based pharmaceutical company. It is a supplier of products delivered to hospitals and pharmacies. Navamedicâs product portfolio consists of prescription and Over The Counter (OTC) pharmaceuticals as well as other healthcare products registered as medical nutrition, medical devices, food supplements or cosmetics. The Companyâs offering is divided into four product areas: Consumer Health, Specialty Pharma, Medical Nutrition and Branded Generics. The Company has one business segment which is the Pharma division. Navamedic ASA is present in all Nordic countries, the Baltics and Benelux. The Company has two subsidiaries, Navamedic AB, through which the Company distributes more than 40 products and a Norway-based Novicus Pharma AS.

Sector

Pharmaceuticals

Calendar

04/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for Navamedic ASA

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

34.5 NOK

Average target price

49 NOK

Spread / Average Target

+42.03%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NAVAMEDIC ASA	-5.99%	5.76Cr
ELI LILLY AND COMPANY	+38.51%	73TCr
NOVO NORDISK A/S	+31.74%	60TCr
JOHNSON & JOHNSON	-6.23%	35TCr
MERCK & CO., INC.	+18.78%	33TCr
ABBVIE INC.	+1.35%	28TCr
ASTRAZENECA PLC	+16.00%	24TCr
NOVARTIS AG	+8.44%	20TCr
ROCHE HOLDING AG	-5.97%	20TCr
AMGEN INC.	+6.19%	16TCr

Other Pharmaceuticals

Navamedic ASA

Equities

NAVA

NO0010205966

Pharmaceuticals

Navamedic ASA Appoints Tom Rönnlund as New Ceo, Effective May 18, 2015

EPS Revisions